Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about DOLUTEGRAVIR: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | DOLUTEGRAVIR |
graph TD
DOLUTEGRAVIR[DOLUTEGRAVIR]
DOLUTEGRAVIR -->|causes| Endoplasmic_Reticulum_Stress[Endoplasmic Reticulum Stress]
DOLUTEGRAVIR -->|activates| PERK[PERK]
DOLUTEGRAVIR -->|activates| IRE1[IRE1]
DOLUTEGRAVIR -->|inhibits| Blood_Brain_Barrier_Integrity[Blood-Brain Barrier Integrity]
DOLUTEGRAVIR -->|targets| Brain_Microvascular_Endothelia[Brain Microvascular Endothelial Cells]
DOLUTEGRAVIR -->|upregulates| Reactive_Oxygen_Species[Reactive Oxygen Species]
DOLUTEGRAVIR -->|upregulates| IL6[IL6]
DOLUTEGRAVIR -->|upregulates| CXCL1[CXCL1]
DOLUTEGRAVIR -->|causes| Neuropsychiatric_Adverse_Effec[Neuropsychiatric Adverse Effects]| Target | Relation | Type | Str |
|---|---|---|---|
| Endoplasmic Reticulum Stress | associated_with | process | 0.95 |
| Endoplasmic Reticulum Stress | causes | process | 0.95 |
| PERK | activates | protein | 0.92 |
| IRE1 | activates | protein | 0.92 |
| Brain Microvascular Endothelial Cells | targets | cell_type | 0.90 |
| Blood-Brain Barrier Integrity | associated_with | phenotype | 0.90 |
| Blood-Brain Barrier Integrity | inhibits | phenotype | 0.90 |
| Reactive Oxygen Species | upregulates | process | 0.88 |
| IL6 | upregulates | gene | 0.87 |
| CXCL1 | upregulates | gene | 0.87 |
| Neuropsychiatric Adverse Effects | causes | phenotype | 0.80 |
| Inflammatory Cytokines And Chemokines | increases | protein | 0.80 |
| ENDOPLASMIC RETICULUM STRESS | induces | process | 0.80 |
| BLOOD-BRAIN BARRIER | disrupts | cell_type | 0.80 |
| eIF2α | activates | protein | 0.80 |
| Tight Junction Proteins | downregulates | protein_complex | 0.80 |
| Neuropsychiatric Adverse Effects | risk_factor_for | phenotype | 0.75 |
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| No targeting hypotheses | |||
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| No papers found | ||||
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning DOLUTEGRAVIR in their description or question text
No additional research found